Cetuximab

Generic Name
Cetuximab
Brand Names
Erbitux
Drug Type
Biotech
Chemical Formula
-
CAS Number
205923-56-4
Unique Ingredient Identifier
PQX0D8J21J
Background

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...

Indication

Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...

Associated Conditions
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

First Posted Date
2022-02-24
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
400
Registration Number
NCT05253651
Locations
🇺🇸

Palo Verde Cancer Specialists, Glendale, Arizona, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

and more 229 locations

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

First Posted Date
2022-02-21
Last Posted Date
2024-11-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT05249426
Locations
🇯🇵

Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan

🇪🇸

Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

and more 21 locations

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

First Posted Date
2022-02-15
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT05239741
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China

🇨🇳

Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China

🇨🇳

Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China

and more 29 locations

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

First Posted Date
2022-02-07
Last Posted Date
2024-11-12
Lead Sponsor
Pfizer
Target Recruit Count
35
Registration Number
NCT05226871
Locations
🇨🇳

Mackay Memorial Hospital, Taipei, Taiwan

🇲🇽

Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo LEÓN, Mexico

🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

and more 13 locations

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

First Posted Date
2022-02-01
Last Posted Date
2023-11-14
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
57
Registration Number
NCT05217069
Locations
🇩🇪

Ludwig Maximilians University, Munich, Germany

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

First Posted Date
2022-02-01
Last Posted Date
2024-11-13
Lead Sponsor
Pfizer
Target Recruit Count
101
Registration Number
NCT05217446
Locations
🇺🇸

Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Hospital, Phoenix, Arizona, United States

🇫🇷

Institut Régional du Cancer Montpellier, Montpellier, France

and more 106 locations

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

First Posted Date
2022-01-20
Last Posted Date
2024-05-02
Lead Sponsor
University of Chicago
Target Recruit Count
53
Registration Number
NCT05200442
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

First Posted Date
2022-01-18
Last Posted Date
2024-08-20
Lead Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Target Recruit Count
48
Registration Number
NCT05194995
Locations
🇨🇳

Research site31, Beijing, Beijing, China

🇨🇳

Research site01, Beijing, Beijing, China

🇨🇳

Research site02, Beijing, Beijing, China

and more 14 locations

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

First Posted Date
2021-12-22
Last Posted Date
2024-08-22
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
80
Registration Number
NCT05167409
Locations
🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

Rutgers Cancer insititute, New Brunswick, New Jersey, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

and more 1 locations

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

First Posted Date
2021-12-16
Last Posted Date
2023-06-08
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
90
Registration Number
NCT05160896
Locations
🇨🇳

the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy